Brokerages Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Price Target at $175.00

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) have been given an average recommendation of “Moderate Buy” by the fifteen research firms that are presently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $175.00.

Several brokerages have recently issued reports on JAZZ. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. JPMorgan Chase & Co. lifted their price objective on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. Royal Bank of Canada raised their target price on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an “outperform” rating in a report on Wednesday, October 23rd. Wells Fargo & Company decreased their price target on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a research note on Thursday, August 1st. Finally, Robert W. Baird dropped their price objective on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a research report on Thursday, August 1st.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the transaction, the chief executive officer now owns 428,976 shares of the company’s stock, valued at $47,547,699.84. This trade represents a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 6,110 shares of company stock worth $720,160. Corporate insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in Jazz Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock worth $776,551,000 after purchasing an additional 84,941 shares during the period. LSV Asset Management grew its holdings in Jazz Pharmaceuticals by 4.2% during the second quarter. LSV Asset Management now owns 2,480,563 shares of the specialty pharmaceutical company’s stock worth $264,750,000 after acquiring an additional 99,705 shares during the period. Pacer Advisors Inc. raised its position in Jazz Pharmaceuticals by 15.3% in the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after acquiring an additional 278,465 shares in the last quarter. Capital World Investors acquired a new stake in Jazz Pharmaceuticals in the first quarter valued at $171,943,000. Finally, Baupost Group LLC MA boosted its position in shares of Jazz Pharmaceuticals by 52.8% during the 2nd quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock worth $136,000,000 after purchasing an additional 440,552 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $121.65 on Thursday. The company has a market cap of $7.35 billion, a P/E ratio of 17.13, a PEG ratio of 1.07 and a beta of 0.57. Jazz Pharmaceuticals has a fifty-two week low of $99.06 and a fifty-two week high of $134.17. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The firm’s 50 day moving average price is $112.22 and its 200 day moving average price is $110.35.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.